Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
暂无分享,去创建一个
Xiaoting Yu | Peng Gao | Kwok-Kin Wong | Fangyu Zhou | Shuai Li | Ting Chen | Andrew J. Aguirre | Jiehui Deng | Yuting Liu | C. Paweletz | Kwok-Kin Wong | Xiaoen Wang | D. Barbie | A. Aguirre | D. Adeegbe | R. Jenkins | G. Herter-Sprie | Cloud P. Paweletz | Xiaoen Wang | Shengwu Liu | Esra A. Akbay | Josephine Hai | Chiara Ambrogio | Long Zhang | Russell W. Jenkins | Dennis O. Adeegbe | Grit S. Herter-Sprie | Laura Gutiérrez-Quiceno | Yanxi Zhang | Ashley A. Merlino | Max M. Quinn | Yu Zeng | Lichao Fan | David A. Barbie | Xianghua Yi | Yanxi Zhang | Shuai Li | Ting Chen | P. Gao | Long Zhang | Yu Zeng | Xianghua Yi | Xiaoting Yu | Jiehui Deng | Shengwu Liu | C. Ambrogio | Yuting Liu | J. Hai | E. Akbay | L. Fan | Fang-yu Zhou | Laura Gutiérrez-Quiceno | Kwok-kin Wong | Lichao Fan
[1] Zhuo Yu,et al. ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells , 2015, OncoTarget.
[2] M. Barbacid,et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma , 2016, Nature Medicine.
[3] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[4] H. Huynh,et al. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma , 2015, Molecular Cancer Therapeutics.
[5] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[6] P. Johnston,et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.
[7] S. Cook,et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.
[8] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[9] M. Edelman,et al. Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic’s View , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] Guocheng Yuan,et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[11] A. Ashworth,et al. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment , 2012, Nature Reviews Clinical Oncology.
[12] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[13] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[14] D. Planchard,et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] S. Carr,et al. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. , 2018, Cancer research.
[16] Zhi Wei,et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.
[17] J. Yang,et al. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer , 2015, Current opinion in oncology.
[18] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[19] A. Adjei,et al. The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.
[20] R. Salgia,et al. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.
[21] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[22] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[23] Andrew L. Kung,et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.
[24] Travis J Cohoon,et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice , 2014, Genes & development.
[25] Maria Kavallaris,et al. Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.
[26] Arnaud Boyer,et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.
[27] N. Ratner,et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.
[28] P. Poulikakos,et al. Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.
[29] P. Jänne,et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial , 2017, JAMA.
[30] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[31] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[32] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[33] Haiyun Wang,et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS , 2018, Cell.
[34] Patricia Greninger,et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.
[35] D. Melton,et al. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance , 2012, Oncogene.
[36] P. Jänne,et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer , 2015, British Journal of Cancer.
[37] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[38] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[39] R. Palmer,et al. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.
[40] Roger D Kamm,et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.